查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298247

神經退行性藥物市場：按藥物類別、適應症、分銷渠道：2021-2031 年全球機會分析和行業預測

Neurodegenerative Drugs Market By Drug Class, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 300 Pages | 商品交期: 2-3個工作天內

價格

2021年神經退行性疾□□病市場價值為362.772億美元，預計2031年將達到748.0938億美元，2022年至2031年的複合年增長率為7.5%。

神經退行性疾□□病是指主要影響大腦和脊髓中的神經元（神經細胞）並導致逐漸退化的一組疾病。 這些疾病通常是進行性和慢性的，症狀隨著時間的推移而惡化。 神經退行性疾□□病的例子包括阿爾茨海默病、帕金森病、亨廷頓病、肌萎縮側索硬化症（ALS）和多發性硬化症（MS）。 這些疾病對人的認知、運動和感覺功能產生深遠影響，並最終導致殘疾和死亡。

神經退行性疾□□病藥物市場-IMG1

用於治療神經退行性疾□□病的藥物旨在減緩疾病的進展或緩解症狀。 使用的具體藥物取決於所治療的神經退行性疾□□病的類型。 例如，用於治療阿爾茨海默病的藥物包括膽鹼酯□抑製劑和美金剛，用於治療帕金森病的藥物包括左旋多巴、多巴胺激動劑和MAO-B抑製劑。

推動全球神經退行性疾□□病市場增長的一個主要因素是對控制神經退行性疾□□病相關症狀的先進藥物的需求不斷增長。 此外，神經退行性疾□□病的強大管道是一個關鍵的市場趨勢，預計將推動市場增長。 患者數量的顯著增加導致對該藥物的需求增加。 然而，與藥物開發過程相關的並發症和藥物副作用預計將阻礙市場增長。

與此同時，尚未開發的新興市場的高增長潛力、多發性硬化症治療藥物 BAF312 和 olerabrutinib 等管道產品的增加以及神經退行性疾□□病藥物的持續批准為市場參與者提供了機會。 例如，2020年1月，諾華公司宣佈歐盟委員會（EC）已批准用於治療以復發或炎症活動的放射學特徵為證據的活動性繼發進行性多發性硬化症（SPMS）成年患者。宣布批准Maygent（siponimod）用於治療癌症。

內容

第一章簡介

第 2 章執行摘要

第三章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 協調員
      • 神經退行性疾□□病增加
      • 政府和非政府組織的努力
      • 預測期內新藥上市的可能性
    • 阻礙因素
      • 與藥物開發相關的並發症
    • 機會
      • 增加研發活動
  • COVID-19 對市場的影響分析

第 4 章：神經退行性疾□□病藥物市場：按藥物類別

  • 概述
    • 市場規模和預測
  • 多巴胺激動劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 脫羧□抑製劑
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 膽鹼酯□抑製劑
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 免疫調節劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 5 章：神經退行性藥物市場：按適應症分類

  • 概述
    • 市場規模和預測
  • 帕金森病
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 阿爾茨海默病
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 多發性硬化症
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 6 章：神經退行性藥物市場：按分銷渠道劃分

  • 概述
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 在線提供商
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 藥店和零售藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 7 章：神經退行性藥物市場：按地區

  • 概述
    • 市場規模和預測：按地區劃分
  • 北美
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類別劃分
    • 市場規模和預測：按適應症分類
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類別劃分
    • 市場規模和預測：按適應症分類
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 歐洲其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類別劃分
    • 市場規模和預測：按適應症分類
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 亞太地區其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類別劃分
    • 市場規模和預測：按適應症分類
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分
      • 其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別劃分
      • 市場規模和預測：按適應症分類
      • 市場規模和預測：按分銷渠道劃分

第 8 章競爭格局

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競賽儀表板
  • 比賽熱圖
  • 頂級公司定位（2021 年）

第 9 章公司簡介

  • Novartis AG
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Orion Corporation
  • Sun Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Viatris Inc.
  • Biogen
Product Code: A13213

The neurodegenerative drugs market valued for $36,277.20 million in 2021 and is estimated to reach $74,809.38 million by 2031, exhibiting a CAGR of 7.5% from 2022 to 2031. Neurodegenerative diseases refer to a group of disorders that primarily affect the neurons (nerve cells) in the brain and spinal cord, leading to their gradual degeneration. These diseases are usually progressive and chronic, and their symptoms worsen over time. Examples of neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). These conditions have a significant impact on a person's cognitive, motor, & sensory functions, and can ultimately lead to disability and death.

Neurodegenerative Drugs Market - IMG1

Drugs used to treat neurodegenerative diseases are medications that are designed to slow down the progression of the disease and/or relieve symptoms. The specific drugs used will depend on the type of neurodegenerative disease being treated. For example, drugs used to treat Alzheimer's disease include cholinesterase inhibitors and memantine, while drugs used to treat Parkinson's disease include levodopa, dopamine agonists, and MAO-B inhibitors.

The major factor that drives the growth of the global neurodegenerative drugs market is rise in demand for advanced drug types for controlling symptoms associated with neurodegenerative diseases. In addition, a strong pipeline for neurodegenerative disease is a key trend in the market, which is expected to fuel the growth of the market. Significant surge in patient population has led to increase in demand for drugs. However, complications associated with drug development process and side effects of drugs are expected to hamper the market growth.

On the other hand, high growth potential in untapped emerging countries, increase in pipeline products such as BAF312 & Orelabrutinib for treating multiple sclerosis disease, and continuous drug approval of neurodegenerative diseases are anticipated to provide lucrative opportunities to the market players. For instance, in January 2020, Novartis AG announced that the European Commission (EC) has approved Mayzent (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.

The neurodegenerative drugs market is segmented into drug class, indication, distribution channel, and region. By drug class, the market is categorized into dopamine agonists, decarboxylase inhibitors, cholinesterase inhibitors, immunomodulators, and others. By indication, the market is segregated into Parkinson's disease, Alzheimer's disease, multiple sclerosis, and others. By distribution channel, the market is classified into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global neurodegenerative drugs market are: AbbVie Inc., Biogen, F. Hoffmann-La Roche Ltd., Novartis AG, Orion Corporation, Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and UCB S.A. Key players operating in the market have adopted product approval, acquisition, collaboration, and agreement as their key strategies to expand their corporate training market share.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neurodegenerative drugs market analysis from 2021 to 2031 to identify the prevailing neurodegenerative drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the neurodegenerative drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global neurodegenerative drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • Dopamine agonist
  • Decarboxylase inhibitors
  • Cholinesterase Inhibitors
  • Immunomodulators
  • Others

By Indication

  • Parkinson's Disease
  • Alzheimer's Disease
  • Multiple Sclerosis
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Orion Corporation
  • Biogen
  • Sanofi
  • Viatris Inc.
  • Novartis AG
  • UCB S.A.
  • AbbVie Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of neurodegenerative diseases
      • 3.4.1.2. Initiatives by government and non-government organizations
      • 3.4.1.3. Expected launch of new drugs during the forecast period
    • 3.4.2. Restraints
      • 3.4.2.1. Complications associated with drug development
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in R&D activities
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Dopamine agonist
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Decarboxylase inhibitors
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Cholinesterase Inhibitors
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Immunomodulators
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: NEURODEGENERATIVE DRUGS MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Parkinson's Disease
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Alzheimer's Disease
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Multiple Sclerosis
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Online Providers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Drug Stores and Retail Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: NEURODEGENERATIVE DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug Class
    • 7.2.3. Market size and forecast, by Indication
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug Class
      • 7.2.5.1.3. Market size and forecast, by Indication
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug Class
      • 7.2.5.2.3. Market size and forecast, by Indication
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug Class
      • 7.2.5.3.3. Market size and forecast, by Indication
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug Class
    • 7.3.3. Market size and forecast, by Indication
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug Class
      • 7.3.5.1.3. Market size and forecast, by Indication
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug Class
      • 7.3.5.2.3. Market size and forecast, by Indication
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug Class
      • 7.3.5.3.3. Market size and forecast, by Indication
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug Class
      • 7.3.5.4.3. Market size and forecast, by Indication
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug Class
      • 7.3.5.5.3. Market size and forecast, by Indication
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug Class
      • 7.3.5.6.3. Market size and forecast, by Indication
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug Class
    • 7.4.3. Market size and forecast, by Indication
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug Class
      • 7.4.5.1.3. Market size and forecast, by Indication
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug Class
      • 7.4.5.2.3. Market size and forecast, by Indication
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug Class
      • 7.4.5.3.3. Market size and forecast, by Indication
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug Class
      • 7.4.5.4.3. Market size and forecast, by Indication
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug Class
      • 7.4.5.5.3. Market size and forecast, by Indication
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug Class
      • 7.4.5.6.3. Market size and forecast, by Indication
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug Class
    • 7.5.3. Market size and forecast, by Indication
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug Class
      • 7.5.5.1.3. Market size and forecast, by Indication
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug Class
      • 7.5.5.2.3. Market size and forecast, by Indication
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drug Class
      • 7.5.5.3.3. Market size and forecast, by Indication
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drug Class
      • 7.5.5.4.3. Market size and forecast, by Indication
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Novartis AG
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. AbbVie Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. F. Hoffmann-La Roche Ltd.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Teva Pharmaceutical Industries Ltd.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Sanofi
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Orion Corporation
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Sun Pharmaceutical Industries Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. UCB S.A.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Viatris Inc.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Biogen
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 02. NEURODEGENERATIVE DRUGS MARKET FOR DOPAMINE AGONIST , BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. NEURODEGENERATIVE DRUGS MARKET FOR DECARBOXYLASE INHIBITORS , BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. NEURODEGENERATIVE DRUGS MARKET FOR CHOLINESTERASE INHIBITORS , BY REGION, 2021-2031 ($MILLION)
  • TABLE 05. NEURODEGENERATIVE DRUGS MARKET FOR IMMUNOMODULATORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. NEURODEGENERATIVE DRUGS MARKET FOR OTHERS , BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 08. NEURODEGENERATIVE DRUGS MARKET FOR PARKINSON'S DISEASE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 09. NEURODEGENERATIVE DRUGS MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. NEURODEGENERATIVE DRUGS MARKET FOR MULTIPLE SCLEROSIS , BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. NEURODEGENERATIVE DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 13. NEURODEGENERATIVE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. NEURODEGENERATIVE DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. NEURODEGENERATIVE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. NEURODEGENERATIVE DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 18. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 19. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 20. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. U.S. NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 22. U.S. NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 23. U.S. NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 24. CANADA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 25. CANADA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 26. CANADA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 27. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 28. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 29. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 30. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 31. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 32. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 33. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 34. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 35. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 36. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 37. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 38. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 39. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 40. UK NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 41. UK NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 42. UK NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 43. ITALY NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 44. ITALY NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 45. ITALY NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 46. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 47. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 48. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 49. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 50. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 51. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 52. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 53. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 54. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 55. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 56. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 57. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 58. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 59. CHINA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 60. CHINA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 61. CHINA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 62. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 63. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 64. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 65. INDIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 66. INDIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 67. INDIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 68. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 69. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 70. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 74. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 75. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 76. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 77. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 78. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 79. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 80. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 81. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 82. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 83. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 84. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 85. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 86. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 87. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 88. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 89. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 90. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 91. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 92. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 93. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 94. NOVARTIS AG: KEY STRATERGIES
  • TABLE 95. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 96. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 97. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 98. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 99. ABBVIE INC.: KEY STRATERGIES
  • TABLE 100. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 101. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 102. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 103. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 106. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 107. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 108. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 109. SANOFI: KEY EXECUTIVES
  • TABLE 110. SANOFI: COMPANY SNAPSHOT
  • TABLE 111. SANOFI: PRODUCT SEGMENTS
  • TABLE 112. SANOFI: PRODUCT PORTFOLIO
  • TABLE 113. ORION CORPORATION: KEY EXECUTIVES
  • TABLE 114. ORION CORPORATION: COMPANY SNAPSHOT
  • TABLE 115. ORION CORPORATION: PRODUCT SEGMENTS
  • TABLE 116. ORION CORPORATION: PRODUCT PORTFOLIO
  • TABLE 117. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 121. UCB S.A.: KEY EXECUTIVES
  • TABLE 122. UCB S.A.: COMPANY SNAPSHOT
  • TABLE 123. UCB S.A.: PRODUCT SEGMENTS
  • TABLE 124. UCB S.A.: PRODUCT PORTFOLIO
  • TABLE 125. UCB S.A.: KEY STRATERGIES
  • TABLE 126. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 127. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 128. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 129. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 130. BIOGEN: KEY EXECUTIVES
  • TABLE 131. BIOGEN: COMPANY SNAPSHOT
  • TABLE 132. BIOGEN: PRODUCT SEGMENTS
  • TABLE 133. BIOGEN: PRODUCT PORTFOLIO
  • TABLE 134. BIOGEN: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. NEURODEGENERATIVE DRUGS MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF NEURODEGENERATIVE DRUGS MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN NEURODEGENERATIVE DRUGS MARKET (2022-2031)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALNEURODEGENERATIVE DRUGS MARKET
  • FIGURE 10. NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR DOPAMINE AGONIST , BY COUNTRY 2021 AND 2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR DECARBOXYLASE INHIBITORS , BY COUNTRY 2021 AND 2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR CHOLINESTERASE INHIBITORS , BY COUNTRY 2021 AND 2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR IMMUNOMODULATORS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR OTHERS , BY COUNTRY 2021 AND 2031(%)
  • FIGURE 16. NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR PARKINSON'S DISEASE, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR ALZHEIMER'S DISEASE, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR MULTIPLE SCLEROSIS , BY COUNTRY 2021 AND 2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 21. NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 25. NEURODEGENERATIVE DRUGS MARKET BY REGION, 2021
  • FIGURE 26. U.S. NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. CANADA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. MEXICO NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. GERMANY NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. FRANCE NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. UK NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. ITALY NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. SPAIN NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. JAPAN NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. CHINA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. INDIA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. BRAZIL NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 44. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49. COMPETITIVE DASHBOARD
  • FIGURE 50. COMPETITIVE HEATMAP: NEURODEGENERATIVE DRUGS MARKET
  • FIGURE 51. TOP PLAYER POSITIONING, 2021
  • FIGURE 52. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 59. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 63. SANOFI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. ORION CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. ORION CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 68. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 69. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 70. UCB S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. UCB S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 73. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 74. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 75. BIOGEN: REVENUE SHARE BY REGION, 2021 (%)